Mar 20, 2006 by Brian GormanFord's Green MachineZero-percent financing for the Escape Hybrid furthers Ford's overall strategy.
Mar 20, 2006 by Brian GormanMuch Ado About PAREXELPAREXEL shares have been on a roller coaster ride lately, but the ups and downs don't make a lot of sense.
Mar 16, 2006 by Brian GormanJoint Strike FightingMajor buyers threaten to bail out of Lockheed Martin's JSF project.
Mar 15, 2006 by Brian GormanAirbus' Chinese FortuneAirbus' investment in China is a shortsighted strategy.
Mar 14, 2006 by Brian GormanAstraZeneca's Heartening NewsA new study shows cholesterol drug Crestor's further potential. Will it help sales?
Mar 13, 2006 by Brian GormanPepsiCo's Diet of ProfitsLow-calorie snack introduced to beef up profits, not consumers.
Mar 9, 2006 by Brian GormanBiodiesel FloodA major investment in biodiesel makes Archer Daniels Midland's own plans look less attractive.
Mar 7, 2006 by Brian GormanTrinity Chugs OnThe railcar manufacturer delivers an impressive 2005 and is poised for a solid 2006.
Mar 3, 2006 by Brian GormanYahoo!'s Fallen StarYahoo!'s flirtation with Hollywood cost it a chance to lead in Web video.
Mar 2, 2006 by Brian GormanMcDonald's and Starbucks' Java JoustResisting McDonald's coffee challenge may cost Starbucks a few customers.
Mar 1, 2006 by Brian GormanHospira's StumbleIn spite of an unsightly quarter, good things still are happening at Hospira.
Feb 28, 2006 by Brian GormanIs Chocolate Hot?Some moves by a few big companies suggest that premium chocolate could be the next major trend.
Feb 27, 2006 by Brian GormanCampbell Soups Up SoupThe soup outfit's new product initiative should give it a major marketing advantage.
Feb 24, 2006 by Brian GormanSyngenta's Potential HarvestThe agricultural technology outfit is developing a seed with lots of potential.
Feb 23, 2006 by Brian GormanADM Pumps Up EthanolThe nation's largest ethanol producer plans to increase the fuel's production; investors should think about the risks.
Feb 21, 2006 by Brian GormanSirius' Stern DilemmaSirius should be extremely cautious about adding too much advertising too soon.
Feb 17, 2006 by Brian GormanEnthusiasm for CephalonThe company seems to be counting on a strong showing for a new drug, but it may pay to be cautious.
Feb 16, 2006 by Brian GormanDaimler's Small StepsThe company makes the right moves, but investors still shouldn't expect miracles.
Feb 14, 2006 by Brian GormanKendle's on Solid GroundThe contract research services outfit is on track for another good year.
Feb 13, 2006 by Brian GormanAlbany Molecular's Royalty SqueezeDeclining royalty revenue is likely to keep buffeting the contract services provider.
